Clinical Trial

Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa

Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to retrospectively analyze the efficacy and safety of secukinumab combined with surgery in treating moderate to severe HS in real-world clinical practice, providing clinical practioners with real-world evidence in HS treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-07.
Trial Details
NCT Number NCT06926192
Lead Sponsor Peking Union Medical College
Conditions Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa), Secukinumab
Enrollment 100 participants
Start Date 2020-01-01
Primary Completion 2024-12-31 (estimated)
Study Completion 2025-06-21 (estimated)
Updated on ClinicalTrials.gov 2025-04-16